Sweetgreen stock rallies to two-year highs after strong revenue growth, hiked outlook. Analysts raise price targets on momentum.
Fox-Doerr murder trial is expected to last more than a week, attorneys say Thursday.
Moderna stock skidded Friday after the FDA delayed an approval decision on its RSV vaccine until the end of the month.